-$0.10 EPS Expected for BioScrip Inc (NASDAQ:BIOS) This Quarter

Analysts predict that BioScrip Inc (NASDAQ:BIOS) will announce earnings per share (EPS) of ($0.10) for the current quarter, according to Zacks. Two analysts have made estimates for BioScrip’s earnings, with estimates ranging from ($0.12) to ($0.07). BioScrip posted earnings per share of ($0.14) in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.23). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.16) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow BioScrip.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $178.96 million for the quarter, compared to analysts’ expectations of $179.23 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year.

Several equities analysts have recently commented on BIOS shares. TheStreet lowered Red Lion Hotels from a “c” rating to a “d+” rating in a research note on Wednesday, April 3rd. BidaskClub raised WhiteHorse Finance from a “sell” rating to a “hold” rating in a research note on Thursday. Barrington Research reaffirmed a “buy” rating and issued a $4.00 price target on shares of BioScrip in a research note on Friday, May 3rd. Finally, Zacks Investment Research raised Hanmi Financial from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $4.60.

Shares of BioScrip stock traded down $0.11 during trading hours on Friday, hitting $2.78. The company’s stock had a trading volume of 532,056 shares, compared to its average volume of 1,177,508. BioScrip has a twelve month low of $1.56 and a twelve month high of $4.14. The company’s fifty day simple moving average is $2.36. The company has a market cap of $369.54 million, a PE ratio of -5.67 and a beta of 0.68.

A number of institutional investors and hedge funds have recently bought and sold shares of BIOS. Squarepoint Ops LLC lifted its stake in shares of BioScrip by 13.7% in the fourth quarter. Squarepoint Ops LLC now owns 52,389 shares of the company’s stock worth $187,000 after acquiring an additional 6,303 shares in the last quarter. Maven Securities LTD bought a new stake in BioScrip in the fourth quarter valued at about $45,000. Perkins Capital Management Inc. increased its holdings in BioScrip by 6.5% in the first quarter. Perkins Capital Management Inc. now owns 231,000 shares of the company’s stock valued at $462,000 after buying an additional 14,000 shares during the last quarter. Caxton Associates LP bought a new stake in BioScrip in the fourth quarter valued at about $52,000. Finally, Gamco Investors INC. ET AL increased its holdings in BioScrip by 2.4% in the first quarter. Gamco Investors INC. ET AL now owns 665,424 shares of the company’s stock valued at $1,331,000 after buying an additional 15,500 shares during the last quarter. 78.60% of the stock is currently owned by hedge funds and other institutional investors.

BioScrip Company Profile

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Recommended Story: What is a balanced fund?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.